Deep Brain Stimulation as a Treatment Approach for Anorexia Nervosa: a Systematic Literature Review

Estimulação cerebral profunda como uma abordagem de tratamento para anorexia nervosa: Uma revisão sistemática de literatura

Ledismar José da Silva1  Tâmara Husein Naciff1  Maria Flávia Vaz de Oliveira1

1 Department of Medicine, Pontifícia Universidade Católica de Goiás, Goiânia, GO, Brazil


Address for correspondence Ledismar José da Silva, Departmento de Medicina, Pontifícia Universidade Católica do Rio de Janeiro, Rua 235, 76 - Setor Leste Universitário, Goiânia, GO, 74175-120, Brazil (e-mail: ledismarsilva@gmail.com).

Keywords
► anorexia nervosa
► eating disorder
► deep brain stimulation
► neuromodulation

Abstract

Anorexia nervosa is a psychiatric disorder characterized by distortions of body size, weight, and shape perception, as well as by food restriction and/or binge and purging behaviors. It mostly affects young women and causes severe negative impacts on their physical, psychological, and social health. Recent studies have analyzed deep brain stimulation (DBS), a neurosurgical procedure that involves electrode implantation in strategical brain areas, to obtain remission of the symptoms of anorexia nervosa. The results showed that the stimulation of areas associated to the neurocircuitry of anorexia nervosa, such as nucleus accumbens, anterior cingulate cortex, ventral striatum, and bed nucleus of the stria terminalis, provokes beneficial responses in terms of body mass index, quality of life, social functioning, and psychiatric comorbidities. Nevertheless, broader investigations are needed to endorse the clinical usage of DBS in the management of anorexia nervosa.

Resumo

A anorexia nervosa é uma desordem psiquiátrica caracterizada pela distorção da percepção de tamanho, peso e formas corporais, bem como por restrição alimentar e/ou comportamentos excessivos e purgativos. Afeta principalmente mulheres jovens e causa grande impacto negativo sobre a sua saúde física, psicológica e social. Estudos recentes analisaram a estimulação cerebral profunda (ECP), um procedimento neurocirúrgico que envolve a implantação de eletrodos em áreas cerebrais estratégicas, como forma de obter remissão dos sintomas da anorexia nervosa. Os resultados demonstraram que a estimulação de regiões que participam da neurocircuitaria da anorexia nervosa, como núcleo acumbens, córtex do cíngulo anterior, estriado e núcleo da estria terminal, provocou respostas benéficas em termos de índice de massa corporal, qualidade de vida, funcionamento social e comorbidades psiquiátricas. No entanto, investigações mais amplas são necessárias para se recomendar a aplicação clínica da ECP no manejo da anorexia nervosa.

Palavras-chave
► anorexia nervosa
► desordem alimentar
► estimulação cerebral profunda
► neuromodulação

Ledismar José da Silva’s ORCID is https://orcid.org/0000-0002-3551-2650.
Introduction

Anorexia nervosa is a debilitating and challenging condition with the highest mortality rate among all the psychiatric disorders, ranging from 6 to 11%. It is characterized by intense fear of putting on weight, persistent and severe restriction of food intake, adoption of behaviors that interfere with weight gain, and disturbed perception of the body weight, size, and shape.

The disorder affects 0.7% of the world population, mainly women (ratio of male to female = 10:1), and, among them, especially teenage girls. The age at onset of anorexia nervosa ranges from 15 to 19 years old in 40% of the cases.

The etiology of anorexia nervosa is complex and multifactorial. Genetic predisposition and personality traits play important roles on the genesis and perpetuation of the disease. Additionally, environmental features such as cultural pressure for thinness and standardized beauty models may trigger the disorder.

It is widely known that anorexia nervosa can have profound effects on people’s health. One of the main consequences of the disease, chronic malnutrition, may lead to severe physical complications, including hydroelectrolytic, gastrointestinal, hepatic, and cardiac disorders, and bone lesions. Furthermore, other psychiatric disorders, such as major depression, generalized anxiety, obsessive compulsive disorder (OCD), and personality disorders, often accompany anorexia nervosa. Also, anorexic patients have a higher risk of eventually becoming addicted to alcohol and drugs.

In spite of all these impairments caused by anorexia nervosa, the evidences that demonstrate the efficacy of the current therapies to treat this disorder are weak. So far, conventional therapeutic approaches have failed to elicit disease remission in nearly 50% of the patients.

Deep brain stimulation (DBS) is a neurosurgical procedure that has been used for almost 30 years to adjust the activity of dysfunctional brain circuits. It exerts effects not only locally, but also on distant targets, through mono and polysynaptic connections. The DBS technique is considered safe and effective for the treatment of Parkinson’s disease and essential tremor. Its use has also been recently extended to some psychiatric disorders, such as major depression, OCD, Tourette syndrome, and Alzheimer disease.

Currently, DBS has been explored as a novel treatment modality for anorexia nervosa. Several studies have shown the use of DBS for the treatment of anorexic patients in experimental trials with promising results.

This study aimed to perform a systematic review of the literature to identify and discuss the indications, outcomes, and side effects of DBS as a treatment approach for patients with anorexia nervosa.

Methods

A systematic literature review was performed aiming to identify the use of DBS for the treatment of people with anorexia nervosa. The search was performed by two independent researchers and followed the steps proposed in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol.

The databases searched for this study were: Medical Literature, Analysis, and Retrieval System Online (MEDLINE), Cochrane Central Register of Controlled Trials (CENTRAL), Latin American and Caribbean Health Sciences Literature (LILACS), Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Health Technology Assessment (HTA), PsycINFO, The Digital Library of Theses and Dissertations of the Universidade de São Paulo (Digital Library USP), Portal de Periódicos da Coordenação de Aperfeiçoamento de Pessoal de Nível Superior do Ministério da Educação (CAPES/MEC), Instituto Brasileiro de Informação em Ciência e Tecnologia (IBICT), ProQuest Dissertations & Theses (PQDT) Global, ClinicalTrials.gov, Registro Brasileiro de Ensaios Clínicos (ReBec), World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), International Standard Randomized Controlled Trials Number (ISRCTN), Australian New Zealand Clinical Trials Registry (ANZCTR), and Deutscher Register Klinischer Studien (DRKS).

The descriptors selected around Boolean operators were: anorexia, OR anorexia nervosa, OR ’eating disorder’, OR binge eating, AND deep brain stimulation, OR DBS, OR neurofunctional surgery, OR electrode implantation, OR neurostimulation, OR neuromodulation, OR psychiatric surgery, and their equivalents in Portuguese, Spanish, German, and French. The terms were searched in all fields of the databases.

The following inclusion criteria were applied for the selection of the studies: 1. articles correlating anorexia nervosa and DBS as a treatment strategy; 2. articles published from 2008 to 2018; 3. articles in English, Portuguese, Spanish, German, and French; 4. articles involving human experimental studies, case reports, and review studies.

The exclusion criteria selected for this review were: 1. duplicate articles; 2. studies involving animal experimentation; 3. articles involving the philosophical and existential implications of DBS. Along the search process in the databases, the keywords deep brain stimulation = ; DBS; neurofunctional surgery; electrode implantation; neurostimulation; neuromodulation and psychiatric surgery have resulted in a considerable amount of studies whose main purpose was to approach existential, ethical and philosophical limitations of the DBS procedure. However, often in the search results, these studies have shown to escape the scope of the present review and were, therefore, excluded; 4. editorials, authors’ comments, or debates; 5. articles addressing any psychiatric disorders other than anorexia nervosa; 6. articles reporting any neurosurgical interventions other than DBS.

The data obtained during this systematic literature review are shown in -Fig. 1.

A total of 74 finished studies were used to perform the review. Nevertheless, we described in the results section only the eight existent experimental studies that applied DBS on patients with anorexia nervosa. The remaining 66 studies were used to compose others sections of this paper, such as introduction, discussion and conclusion, once they were constituted by reviews studies and represent a compilation of the data obtained on the experimental studies.
Results

In this systematic literature review, eight experimental studies were selected for having used DBS for the treatment of patients with anorexia nervosa. Nucleus accumbens (NAc) plays a central role in the reward circuitry. Therefore, it has been used as a target in several studies that aimed to apply a neurosurgical treatment to anorexia nervosa.\textsuperscript{1–3}

Bilateral NAc DBS (stimulation frequency: 180 Hz; pulse width: 90 µs; stimulation voltage: 1–8 V) was performed in 4 female teenagers diagnosed with anorexia nervosa, refractory to conventional treatment. Before surgery, the mean age of the patients was 16.5 years, and the average duration of this disorder was 18.5 months. At the beginning of the study, all the patients had some psychiatric comorbidities, and none of them was attending school due to physical or psychiatric limitations. The patients underwent this neurosurgical procedure between 2007 and 2011, with a mean follow-up period of 38 months (9–50 months) after the surgery. A considerable improvement was observed in the medical conditions of the patients. Their average body mass index (BMI) increased from 11.9 kg/m\textsuperscript{2} at baseline to 19.6 kg/m\textsuperscript{2} at the last follow-up, that is, a 65% increase, no longer meeting the diagnostic criteria for anorexia nervosa.\textsuperscript{1}

Their menstrual cycles became regular in an average period of 6.8 months after the surgery, and the symptoms and comorbidities had a decrease. The average score in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) reduced from 29 to 1.7 and so did the average score in the Hamilton Rating Scale for Anxiety (HAMA), decreasing from 19 to 2. At the end of the study, three out of the four patients returned to school.\textsuperscript{14}

Similar results were found in an independent study that involved eight women with anorexia nervosa, six of whom underwent bilateral stereotactic radiofrequency ablation, and two, bilateral DBS (135–185 Hz; 120–210 µs; 2.5–3.8 V), both procedures having NAc as the target area. After the interventions, all of them increased and became normal 1 year after the surgery. The BMI significantly increased (\(p < 0.001\)) 6 months and 1 year after the procedures. The mean BMI of the patients did not reach the normal range, but it came close to its inferior value of normality. The menstrual cycle became normal in all the patients in a mean period of 4.63 months.\textsuperscript{15}

In both studies, a significant increase regarding intelligence, memory, quality of life, and social functioning, and a significant decrease in nervousity, psychoticism, and tendency to lie were noted. Yale-Brown obsessive-compulsive scale, HAMA, and Hamilton Depression Scale (HAMD) significantly decreased 1 week after the surgeries. No long-lasting adverse events or complications of the procedures were reported.\textsuperscript{14,15}

The glucose metabolism of 6 patients diagnosed with anorexia nervosa and 12 age-matched healthy controls were analyzed using fluorine-18-fluorodeoxyglucose positron emission tomography (\(^{18}\text{F}-\text{FDG-PET}\)). Certain cerebral areas of patients with anorexia nervosa showed hypermetabolism in comparison to healthy controls, namely the frontal lobe, lentiform nucleus, and hippocampus. Bilateral NAc DBS was performed in four of the patients with anorexia nervosa. After the surgical procedure, the cerebral areas with hypermetabolism had a decrease in their metabolism. It was hypothesized that the frontal lobe, the lentiform nucleus, and the hippocampus are responsible for the obsessive symptoms and eating disorders that characterize anorexia nervosa. Nevertheless, larger randomized controlled trials are needed to confirm this evidence.\textsuperscript{16}

A Canadian group focused on the subcallosal cingulate (SCC) as a DBS target for the treatment of anorexia nervosa. In their first study, 6 anorexia nervosa patients underwent bilateral SCC DBS (130 Hz; 90 µs; 3.5 V). At the beginning of the study, the mean age of the patients was 38.3 years, while the average duration of this disease was 18.3 years. A 9-month follow-up after DBS pointed to improvements on the psychiatric condition and quality of life of the patients, with decreases in HAMD (17.8 at baseline versus 10.7 at the end of the study), Beck Depression Inventory (BDI) (38.8 versus 20.2), Y-BOCS (25.0 versus 13.2), and Beck Anxiety Inventory (BAI) (31.2 versus 21.7) scores, and an increase from an average of 57.3 at baseline to 65.8 at the end of the study in the Quality of Life Scale (QOLS or Flanagan score). At

---

\textsuperscript{1}---
the final follow-up, three patients had gained weight and three remained with the same BMI of the pre-surgery phase.3

In the second study of the same Canadian group, the investigation was expanded, enrolling 16 anorexia nervosa patients that were followed for 12 months after SCC DBS (130 Hz; 90 µs; 5–6.5 V). The results point to a significant increase in BMI (13.83 kg/m² at baseline versus 17.34 kg/m² at the final follow-up, \( p = 0.0009 \)), as well as a significant decrease in depression, obsession, compulsion, and anxiety symptoms after 12 months. These outcomes show that the benefits of DBS can be better evaluated with a longer follow-up period.5 Some adverse events, such as pancreatitis, seizure, QT prolongation, hypophosphatemia, refeeding delirium, and worsening of mood, were reported after the procedure. Nevertheless, these events were related to the fragility caused by anorexia nervosa rather than to the DBS procedure.2

Deep brain stimulation has also been used in single-patient studies to treat anorexia nervosa associated with other psychiatric disorders.17–19 A 56-year-old female patient diagnosed with recurrent depression and anorexia nervosa in adolescence underwent DBS in the subgenual cingulate area (intermittent stimulation: 2 minutes on, 1 minute off; 5 mA; 91 µs). Three years after the surgery, her BMI increased from 14.1 to 19.1 and the Eating Attitudes Test (EAT-26) score decreased from 40.56 to 1.0. Even after a depressive episode because of the suicide of a friend, the symptoms of the eating disorder have been under control.17

A 52-year-old female patient with severe OCD since childhood and several comorbidities such as depression, anorexia nervosa, generalized anxiety disorder, and attention-deficit/hyperactivity disorder underwent bilateral ventral striatum DBS (120 Hz; 120 µs; 7.5 V). Her BMI increased from 18.5 kg/m² at baseline to 19.6 kg/m² at follow-up. In addition, the patient revealed to be more comfortable with food after implantation.18

More recently, a 60-year-old female patient with a diagnosis of childhood onset of anxiety and anorexia nervosa presented with symptoms of anxiety connected to food intake, restricted eating, purging, major depressive disorder leading to suicidal ideations and attempts. After years of psychotherapy, several different classes of medication, electroconvulsive therapy, and commitment to a closed psychiatric ward with no improvement whatsoever, she underwent implantation of two DBS electrodes in the medial forebrain bundle (130 Hz; 60 µs; 2.8–3.0 V) with excellent results. However, due to neurological adverse events, the patient was subjected to reoperation 2 years after the first surgery. In the second procedure, bilateral electrodes (130 Hz; 120 µs; 4.3 V) were implanted in the bed nucleus of the stria terminalis (BNST). Although no improvements regarding BMI were observed after the second implantation, her food intake became more stable, the purging episodes disappeared, tube feeding could be discontinued, she was released from the psychiatric ward, and is now living at home with her family.19

All the details about the patients, comorbidities, DBS targets, and outcomes after the procedures in the eight studies selected are summarized in _Table 1_.

## Discussion

The 29 patients diagnosed with anorexia nervosa that underwent DBS selected in this systematic literature review were female, with mean age of 30.9 ± 13.1 years at baseline, ranging from 16 to 60 years old.

The targets for DBS implantation were: SCC, NAc, subgenual cingulate cortex, ventral striatum, medial forebrain bundle and BNST. All these areas and structures participate in the pathological circuit of anorexia nervosa.2,3,14–19 Although all the studies selected reported a beneficial effect of DBS in the clinical presentation of anorexia nervosa, it is still not possible to determine which target was the most effective, due to the great diversity of the subjects treated.

Deep brain stimulation increased the BMI in all patients, except one.19 Additionally, consequences of the disease such as food aversion and psychiatric comorbidities greatly decreased in all studies after DBS intervention. Improvements were achieved in physical and psychiatric aspects of the subjects that underwent this type of treatment, with few or no long-lasting adverse effects resulting from the procedure.2,3,14–19

However, the broad and clinical use of DBS for the treatment of anorexia nervosa symptoms cannot be endorsed yet, because of lack of evidence obtained from standardized, systematic, double-blind, placebo-controlled trials.2,3,6,17 Nonetheless, the perspective for the near future is optimistic, once consolidated clinical trials with the use of sham stimulation and double-blind crossover approach,20 as well as comparing DBS to clinical therapy,21 have been designed.

This systematic literature review had certain limitations due to the small number of studies and patients involved, as well as the lack of standardized inclusion criteria for patients with anorexia nervosa that could benefit from DBS treatment. A well-established definition of anorexia nervosa refractory to clinical treatment is a critical concept that is yet to be determined.

In 2017, a framework was presented to guide researchers through the ethical implications involving the treatment of severe and enduring anorexia nervosa using DBS. It includes steps such as assessing individual needs and possible risks and benefits, considering issues of mental capacity and informed consent, and considering future care after participation in the research.22 Similarly, broader frameworks, involving the clinical, psychological, and social aspects of patients diagnosed with anorexia nervosa should be designed to better guide the patient selection process.

Since the factors involved in the pathophysiology of anorexia nervosa are rather complex and multifaceted, the exact neurocircuitry of this disorder has not been completely elucidated yet.10,14 To this moment, it has not been possible to isolate one single structure or pathway responsible for triggering the symptoms of the disease. Therefore, a model involving multiple circuits has been indicated as the most plausible explanation for the occurrence of the disease.23

Studies conducted to investigate the neurocircuitry of anorexia nervosa often rely on important neuronal targets, whose functions and dysfunctions underly the clinical manifestations of the disease, such as pathologic humor, anxiety,
Table 1 Clinical profiles, comorbidities, stimulation targets, and outcomes of patients diagnosed with anorexia nervosa that underwent deep brain stimulation (DBS) in eight studies selected in this systematic literature review

<table>
<thead>
<tr>
<th>Patients (n)</th>
<th>Clinical profile</th>
<th>Comorbidity</th>
<th>DBS target</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>1. 16 years old; female; AN duration: 28 months; amenorrhea duration: 11 months; suspension from school: 5 months; BMI at baseline: 12.2 kg/m²; medication: SSRI; olanzapine</td>
<td>OCD</td>
<td>NAc</td>
<td>After a mean follow-up of 38 months – average BMI: 19.6 kg/m² (increased by 65%); Y-BOCS decreased from 29 to 1.7; HAMA decreased from 19 to 2; menses returned within an average period of 6.8 months; three patients returned to school</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>2. 16 years old; female; AN duration: 18 months; amenorrhea duration: 15 months; suspension from school: 3 months; BMI at baseline: 13.3 kg/m²; medication: SSRI; olanzapine</td>
<td>OCD</td>
<td>NAc</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. 17 years old; female; AN duration: 15 months; amenorrhea duration: 9 months; suspension from school: 10 months; BMI at baseline: 12 kg/m²; medication: SSRI; olanzapine</td>
<td>GAD</td>
<td>NAc</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. 16 years old; female; AN duration: 13 months; amenorrhea duration: 9 months; suspension from school: 6 months; BMI at baseline: 10 kg/m²; medication: SSRI</td>
<td>OCD</td>
<td>NAc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1. 28 years old; female; AN duration: 2 years; BMI at baseline: 13.3 kg/m²; vital signs at baseline – temperature: 35.5°C; heart rate: 47 bpm; blood pressure: 91 × 60 mm Hg; HAMD: 24; HAMA: 35</td>
<td>Not reported</td>
<td>NAc</td>
<td>1 year after surgery – BMI: 18 kg/m²; temperature: 36.4°C; heart rate: 71 bpm; blood pressure: 107 × 71 mm Hg; HAMD: 9; HAMA: 8</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>2. 18 years old; female; AN duration: 3 years; BMI at baseline: 12.9 kg/m²; vital signs at baseline – temperature: 35.6°C; heart rate: 48 bpm; blood pressure: 82 × 60 mm Hg; HAMD: 20; HAMA: 24</td>
<td>Not reported</td>
<td>NAc</td>
<td>1 year after surgery – BMI: 20.8 kg/m²; temperature: 36.3°C; heart rate: 69 bpm; blood pressure: 96 × 66 mm Hg; HAMD: 9; HAMA: 7</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1. 18 years old; female; AN duration: 13 months; amenorrhea duration: 4 months; suspension from school: 2 months; BMI at baseline: 11.8 kg/m²; medication: SSRI</td>
<td>Not reported</td>
<td>NAc</td>
<td>1 month after surgery – BMI: 17.9 kg/m²; no medication</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>2. 16 years old; female; AN duration: 28 months; amenorrhea duration: 11 months; suspension from school: 5 months; BMI at baseline: 11.2 kg/m²; medication: SSRI; olanzapine</td>
<td>Not reported</td>
<td>NAc</td>
<td>1 month after surgery – BMI: 13.1 kg/m²; no medication</td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Patients (n)</th>
<th>Clinical profile</th>
<th>Comorbidity</th>
<th>DBS target</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. 16 years old; female; AN duration: 18 months; amenorrhea duration: 15 months; suspension from school: 3 months; BMI at baseline: 13.3 kg/m²; medication: SSRI, olanzapine</td>
<td>Not reported</td>
<td>NAc</td>
<td>1 month after surgery—BMI: 14.5 kg/m²; no medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. 16 years old; female; AN duration: 42 months; amenorrhea duration: 24 months; suspension from school: 12 months; BMI at baseline: 12.2 kg/m²; medication: SSRI</td>
<td>Not reported</td>
<td>NAc</td>
<td>1 month after surgery—BMI: 17.1 kg/m²; no medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>1. 24 years old; female; AN duration: 10 years; lowest BMI: 11 kg/m²</td>
<td>MDD; anxiety</td>
<td>SCC</td>
<td>Significant increase in BMI ($p = 0.0009$) and QOLS ($p = 0.021$); significant decrease in Y-BOCS ($p = 0.023$), HAMD ($p = 0.00015$), BDI ($p = 0.0022$), BAI ($p = 0.035$), DERS ($p = 0.019$), YBC-EDS-p ($p = 0.0025$), and YBC-EDS-r ($p = 0.0013$) scores</td>
<td>2,3</td>
</tr>
<tr>
<td></td>
<td>2. 38 years old; female; AN duration: 21 years; lowest BMI: 11.9 kg/m²</td>
<td>MDD; PTSD; SUD; OCD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. 35 years old; female; AN duration: 15 years; lowest BMI: 12.4 kg/m²</td>
<td>MDD; PTSD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. 40 years old; female; AN duration: 10 years; lowest BMI: 13.1 kg/m²</td>
<td>MDD; PTSD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5. 35 years old female; AN duration: 19 years; lowest BMI: 13.5 kg/m²</td>
<td>MDD; PTSD; GAD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6. 57 years old; female; AN duration: 27 years; lowest BMI: 13.0 kg/m²</td>
<td>None</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7. 21 years old; female; AN duration: 9 years; lowest BMI: 11.2 kg/m²</td>
<td>MDD; OCD; GAD; BPD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8. 32 years old; female; AN duration: 19 years; lowest BMI: 12.9 kg/m²</td>
<td>MDD; PTSD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9. 26 years old; female; AN duration: 14 years; lowest BMI: 14.8 kg/m²</td>
<td>PTSD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10. 30 years old; female; AN duration: 19 years; lowest BMI: 10.6 kg/m²</td>
<td>MDD; OCD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11. 39 years old; female; AN duration: 24 years; lowest BMI: 10.3 kg/m²</td>
<td>MDD; PTSD; OCD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12. 39 years old female; AN duration: 29 years; lowest BMI: 7.2 kg/m²</td>
<td>PTSD; GAD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13. 32 years old; female; AN duration: 20 years; lowest BMI: 11.4 kg/m²</td>
<td>MDD; PTSD; OCD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14. 34 years old; female; AN duration: 19 years; lowest BMI: 15.1 kg/m²</td>
<td>MDD; anxiety; PTSD</td>
<td>SCC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
eating disorders, distorted body perception, inhibition, and alexithymia. For that matter, neuroimaging techniques such as 18F-FDG-PET, single-photon emission computed tomography (SPECT), and functional magnetic resonance imaging (fMRI) have been of great assistance, once functional and structural differences are found between the brains of anorexic patients and healthy individuals.

Most of these differences can be observed in the limbic lobe, in the pre-frontal cortex, and in the cingulate cortex, areas responsible for the management of emotions and behavior. For instance, the components of the reward system, especially NAC, which belong to the cortex–striatum–thalamus–cortical circuit, are dysfunctional in anorexic individuals. Such dysfunction explains why food, naturally a primary reinforcer, is likely to trigger an appetite-aversion response in anorexia nervosa patients.

Also, anorexic patients are prone to consider themselves heavier and larger compared with other people. This pathological feature may be explained by the reduced activity of the parietal cortex in anorexic patients, as shown by SPECT, positron emission tomography (PET), and fMRI. The parietal cortex is responsible for the visuospatial abilities and the construction of body image; therefore, its hypoactivity contributes to the distorted self-perception in anorexia nervosa patients.

Another distinctive finding in patients with anorexia nervosa is mood and affective disorders, partly derived from dysfunctional actions of the ventromedial prefrontal cortex and orbitofrontal cortex, which stimulate non-adaptive behaviors, such as self-starvation and self-harm, in these individuals. In addition to this, fMRI studies have revealed hypoactivity in the ventral striatum, supplementary motor area, and frontal-striatal circuits in anorexic patients, which may justify the low levels of cognitive flexibility of these individuals. Moreover, the subcallosal and subgenual cingulate cortex are involved in major depressive disorder, OCD, and abnormal mood seen in anorexia nervosa patients.

Positron emission tomography/SPECT studies have also demonstrated the presence of abnormalities in the dopamine...
and serotonin systems in anorexic patients. It seems that anxiety manifestations, behavioral inhibition, and body image distortions are associated with alterations in 5-HT1A and 5-HT1B receptors, as well as in serotonin transporters in limbic and cortical structures. Dopamine is pathologically increased in the brain of anorexic patients, leading to anxiety symptoms, which are alleviated through starvation.\textsuperscript{14}

### Conclusion

Anorexia nervosa is a debilitating and, in some instances, lethal disorder. Deep brain stimulation has been used experimentally in multiple targets of the neurocircuitry of anorexia nervosa, such as NAc, SCC, striatum, subgenual cingulate, and BNST. The results have shown that DBS is a safe and effective method in the regression of the symptoms of this disease. However, it is important to emphasize that DBS is still an experimental approach for the treatment of anorexia nervosa. Therefore, a larger number of studies with a broader scope is needed in order for the clinical use of DBS can be recommended.

### Conflicts of Interest

The authors have no conflicts of interest to declare.

### References